Journal of Headache and Pain

Papers
(The TQCC of Journal of Headache and Pain is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019473
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates369
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update200
Migraine and neuroinflammation: the inflammasome perspective132
Comorbidities of primary headache disorders: a literature review with meta-analysis97
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)91
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs79
Long COVID headache78
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace73
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials73
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects68
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine68
Applying a biopsychosocial model to migraine: rationale and clinical implications60
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months59
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism54
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients53
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)52
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis50
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study44
Medication overuse and drug addiction: a narrative review from addiction perspective43
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance43
Association between response to triptans and response to erenumab: real-life data42
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine42
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis41
Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 202040
Inflammatory complications of CGRP monoclonal antibodies: a case series40
Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine38
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients38
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study38
Is there a causal relationship between stress and migraine? Current evidence and implications for management37
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension37
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description37
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study36
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes36
Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study36
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study35
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine35
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis34
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention34
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period34
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure33
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine32
Immunogenicity of biologic therapies for migraine: a review of current evidence30
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine30
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice30
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury29
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions29
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i27
Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities27
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials27
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid26
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation26
Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE225
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience25
Gray and white matter abnormalities in primary trigeminal neuralgia with and without neurovascular compression24
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis24
The Global Campaign turns 18: a brief review of its activities and achievements24
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study24
Brain barriers and their potential role in migraine pathophysiology24
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients24
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database23
Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea23
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension23
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study23
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine22
Altered brain functional network dynamics in classic trigeminal neuralgia: a resting-state functional magnetic resonance imaging study22
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy22
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch22
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study22
What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials22
The role of deficient pain modulatory systems in the development of persistent post-traumatic headaches following mild traumatic brain injury: an exploratory longitudinal study22
Whole-brain morphological alterations associated with trigeminal neuralgia22
Demoralization predicts suicidality in patients with cluster headache21
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States21
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures21
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study21
The patients’ perspective on the burden of idiopathic intracranial hypertension21
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience21
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology20
21st century headache: mapping new territory20
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience20
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine20
Association between migraine and cognitive impairment19
A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan19
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study19
Assessment of normalized cerebral blood flow and its connectivity with migraines without aura during interictal periods by arterial spin labeling19
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries19
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana19
Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study19
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany19
FKN/CX3CR1 axis facilitates migraine-Like behaviour by activating thalamic-cortical network microglia in status epilepticus model rats19
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study19
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model19
Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire19
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials19
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis19
Cerebral perfusion variance in new daily persistent headache and chronic migraine: an arterial spin-labeled MR imaging study19
3.875962972641